CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Fennec Pharmaceuticals (FENC) suffers setback from FDA

By Andrew Knoll

19:37, 30 November 2021

A pharmaceutical lab.
A typical pharmaceutical lab - Photo: Shutterstock

Fennec Pharmaceuticals (FENC) failed to gain US Food and Drug Administration approval for its only product in clinical trials, PEDMARK, and shares plummeted on Monday then fell further on Tuesday.

The FDA raised issues with Fennec’s production facility for PEDMARK, a treatment to prevent hearing loss in paediatric cancer patients.

The two parties will now seek to schedule a Type A meeting to discuss what measures need to be taken before another New Drug Application can be submitted. This was the second FDA rejection of a Fennec NDA for PEDMARK, with both decisions based on manufacturing facility deficiencies.

Those delays did not play favourably in the market as shares lost more than half their value, dropping from $9.64 at close on Friday, all the way to $4.37 during Tuesday’s mid-day trading.

Fennec stock had gained nearly 30% over the course of the year and was trading near its 52-week high prior to Monday’s development. Shares hit a 14-month low on Monday and continued to tumble on Tuesday.

PEDMARK’s potential

The FDA bestowed a Breakthrough Therapy and Fast Track Designation in 2018 upon PEDMARK.

It could become the first preventive treatment on the market to combat ototoxicity – the overarching term for hearing loss, equilibrium deficits and ringing in the ears – in paediatric cancer patients who received platinum-based chemotherapy. In the US and Europe, more than 10,000 paediatric patients undergo platinum-based chemotherapy annually.


132.70 Price
+6.630% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.19


15.47 Price
+6.750% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.13


468.65 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.31


146.71 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

Cisplatin and other platinum-based compounds have become key components in treating paediatric brain, bone and other cancers, but have been known to cause hearing loss, deafness and balance issues in patients.

Not only are young patients often left with a lifetime of costly and cumbersome treatments, such as hearing aids or cochlear implants, but speech, reading and other aspects of development can be hindered significantly.

Fennec said that a pair of Phase 3 clinical studies had shown promising results for PEDMARK’s ability to abate hearing loss in paediatric patients.

Potential class action

A Philadelphia law firm wasted little time in launching an investigation and sowing the seeds of a potential securities class-action lawsuit on Tuesday.

Kehoe Law Firm issued a news release encouraging any Fennec investors with losses of $25,000 or greater to fill out a securities class-action questionnaire. Neither Kehoe nor Fennec responded to phone inquiries from

“Kehoe Law Firm, P.C. is investigating whether Fennec Pharmaceuticals Inc. violated federal securities laws or engaged in other unlawful business practices,” the release read.

Read more: Cumberland Pharmaceuticals (CPIX) soars on FDA label approval

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading